tetano
Editor, Senior Moderator
Case Rep Oncol
. 2023 Nov 3;16(1):1287-1292.
doi: 10.1159/000533821. eCollection 2023 Jan-Dec. Oral Chronic Graft-versus-Host Disease in Post-Hematopoietic Stem Cell Transplant Patients Following SARS-CoV-2 Vaccination: Case Reports
Joel B Epstein[SUP] 1 2 [/SUP], Raymond S Hernandez[SUP] 1 [/SUP], Ryotaro Nakamura[SUP] 1 [/SUP], Susan E Yost[SUP] 3 [/SUP], Haris Ali[SUP] 1 [/SUP]
Affiliations
Patients receiving allogeneic hematopoietic stem cell transplant may experience graft-versus-host disease (GVHD) in which donor immune cells cause an immune reaction in host tissues. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines are highly effective in prevention of severe coronavirus-2019 (COVID-19) disease, but the vaccine can result in immune activation and GVHD. Herein, we report 4 cases of oral manifestations that may have been stimulated by COVID-19 or vaccination with Pfizer or Moderna vaccines. We believe this study is the first to report oral changes driven by an inflammatory/immune mechanism leading to oral symptomatic cGVHD. The clinical impact of this study is early recognition and appropriate management of oral symptomatic cGVHD following COVID-19 disease or SARS-CoV-2 vaccination.
Keywords: Case report; Graft-versus-host disease; SARS-CoV-2; Vaccination.
. 2023 Nov 3;16(1):1287-1292.
doi: 10.1159/000533821. eCollection 2023 Jan-Dec. Oral Chronic Graft-versus-Host Disease in Post-Hematopoietic Stem Cell Transplant Patients Following SARS-CoV-2 Vaccination: Case Reports
Joel B Epstein[SUP] 1 2 [/SUP], Raymond S Hernandez[SUP] 1 [/SUP], Ryotaro Nakamura[SUP] 1 [/SUP], Susan E Yost[SUP] 3 [/SUP], Haris Ali[SUP] 1 [/SUP]
Affiliations
- PMID: 37928865
- PMCID: PMC10624449
- DOI: 10.1159/000533821
Patients receiving allogeneic hematopoietic stem cell transplant may experience graft-versus-host disease (GVHD) in which donor immune cells cause an immune reaction in host tissues. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines are highly effective in prevention of severe coronavirus-2019 (COVID-19) disease, but the vaccine can result in immune activation and GVHD. Herein, we report 4 cases of oral manifestations that may have been stimulated by COVID-19 or vaccination with Pfizer or Moderna vaccines. We believe this study is the first to report oral changes driven by an inflammatory/immune mechanism leading to oral symptomatic cGVHD. The clinical impact of this study is early recognition and appropriate management of oral symptomatic cGVHD following COVID-19 disease or SARS-CoV-2 vaccination.
Keywords: Case report; Graft-versus-host disease; SARS-CoV-2; Vaccination.